Our website is set to 'allow cookies' to give you the best experience without telling us who you are. Please continue if you consent to this, or click below to change your settings:

Change settings

Find out more about our cookies policy


Hot Topics

View all hot topics


EmTech 2014

23-25 September 2014

We will be presenting on 'Medical Mobile Apps: Revolutionizing healthcare' at MIT Technology Review's EmTech Conference.

» Find out more

RoboBusiness 2014

15-17 October 2014

Consultants from Sagentia will be attending this RoboBusiness event at the Hynes Convention Center in Boston, MA.

» Find out more

Press Releases

Sagentia partners with Premaitha Health to develop first to market non-invasive diagnostic for prenatal screening

21 July 2014

Sagentia is working with Premaitha Health, a molecular diagnostics company based in Manchester UK, to develop Premaitha’s IONA® test. It will be the first complete non-invasive in vitro diagnostic product for prenatal screening to determine the likelihood of a trisomy affected pregnancy such as Down’s Syndrome. Sagentia will develop the custom clinical bioinformatics analysis application that performs the test analysis, computes test results and generates test reports.

» Find out more

Sagentia leads discussion on intelligent adherence monitoring for drug delivery

26 June 2014

Sagentia is today presenting to industry experts at Management Forum’s Dry Powder Inhaler Conference in London. Sagentia’s Dr Gregory Berman, Head of Advanced Drug Delivery, will be discussing intelligent adherence monitoring for pulmonary drug delivery as part of the event’s focus on new technologies and developments in dry powder inhalers (DPIs).

» Find out more

Press Coverage

Sagentia and Premaitha partner on commercial software for NGS-based NIPT product

11 August 2014

GenomeWeb interviews Sagentia's SVP Medical, Paul Wilkins, and Premaitha's CEO Stephen Little on the recent announcement that Premaitha has selected Sagentia to develop a custom bioinformatics solution for Premaitha's NGS-based NIPT product. 

» Find out more

Sagentia's partner SetPoint Medical talks to the NY Times about their implantable neuromodulation devices

12 June 2014

Article in the NY Times with Sagentia partner SetPoint Medical on their technological advances in treating patients with debilitating inflammatory diseases using proprietary implantable neuromodulation devices.

» Find out more

Why choose Sagentia?

Experts in complex science & technology

Multidisciplinary, cross sector team approach

Excel at meeting aggressive timescales

Customer friendly approach
to IP

Accreditation to ISO 9001 and ISO 13485

What our clients say:

"We would have no hesitation in working with Sagentia again and have recommended the team for other initiatives"

RSS Feeds

Keep track of site upates using our RSS feeds, click a link below to view the feed.

Press enquiries

For further information and media enquiries please email